Wang 2008c.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: one week washout period + eight weeks intervention. Design: parallel. Setting: inpatient and outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. SANA of 60 or more. N = 86. Age: aripiprazole group: mean = (29.4 ± 7.6) years; ziprasidone group: mean = (30.3 ± 8.1) years. Gender: not reported. History: aripiprazole group: mean = (5.5 ± 2.8) years; ziprasidone group: mean = (5.2 ± 2.7) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 10‐30 mg/day, mean = (16.7 ± 1.4) mg/day. N = 43. 2. Ziprasidone: Dose range: 20‐80 mg/day, mean = (46. 3 ±10. 3) mg/day. N = 43.
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25%). CGI‐GI total score. Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score. SANS total score score. Adverse effects. Unable to use ‐ Mental state: SANS subscale score ‐ unvalidated subscale.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Data on TESS score, blood and urine routine, ECG. were missing.
Other bias	Low risk	None obvious.